Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05907096 | ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function | PHASE2 | ACTIVE NOT_RECRUITING | 103 | — | — | Feb 17, 2024 | Jul 31, 2026 | Mar 18, 2026 | 45 | United States, Australia +9 |
Estimated glomerular filtration rate
| Arm | Type | Description |
|---|---|---|
| ARGX-117 | EXPERIMENTAL | Patients receiving ARGX-117 intravenous infusions |
| Placebo | PLACEBO_COMPARATOR | Patients receiving placebo intravenous infusions |
| Name | Type | Description |
|---|---|---|
| ARGX-117 | BIOLOGICAL | Intravenous administration of ARGX-117 |
| Placebo | OTHER | Intravenous administration of placebo |
Inclusion Criteria: * Is at least the local legal age of consent for clinical studies and at least aged 18 years and less than 70 years * Agree to use contraceptive measures consistent with local regulations * Are diagnosed with ESRD and have been stable on chronic dialysis for at least 3 months * ...